(1S, 2S, 3R, 4R)-3-(5-Fluoro-2-(3-methyl-4-(4-methylpiperazin-1-yl)-phenylamino)-pyrimidin-4-ylamino)bicycle[2.2.1]hept-5-ene-2-carboxamide benzoate

(1S, 2S, 3R, 4R)-3-(5-Fluoro-2-(3-methyl-4-(4-methylpiperazin-1-yl)-phenylamino)-pyrimidin-4-ylamino)bicycle[2.2.1]hept-5-ene-2-carboxamide benzoate
Trade Name
Orphan Indication Acute myeloid leukemia
USA Market Approval USA
USA Designation Date 2010-01-19 00:00:00
Sponsor EMD Serono, Inc.;1 Technology Place;Rockland, Massachusetts, 02370
Related Access Program
Children’s Hospital Los Angeles – Acute myeloid leukemia Jazz Pharmaceuticals – Secondary AML Celator Pharmaceuticals – Secondary AML University of California, San Francisco – Acute myeloid leukemia Emory University – Acute myeloid leukemia